Orum Therapeutics
Daejeon
About Orum Therapeutics
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibody therapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $190.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: krx:475830
- Website: orumrx.com
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/orum-therapeutics-51061 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.